The purpose of this study is to assess whether the changes in gut hormones seen following Roux en Y Gastric Bypass surgery are responsible for some of the beneficial effects seen post-operatively.
This study is designed to investigate whether chronic elevation of glucagon-like peptide-1 (GLP-1), oxyntomodulin and peptide YY (PYY) in combination is responsible for the majority of the metabolic effects of Roux-en-Y gastric bypass (RYGB) including improved glycaemia, increased energy expenditure, reduced food intake, weight loss, reduced preference for high calorie foods and reduced activation in brain reward areas in response to visual food cues.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
190
NIHR/Wellcome Trust Imperial CRF, Hammersmith Hospital
London, Greater London, United Kingdom
RECRUITINGWeight loss
Weight loss as measured at baseline compared to 4 weeks after infusion or diet
Time frame: Baseline - 4 weeks
Glycaemia
As assessed by change in fructosamine and HbA1c levels
Time frame: Baseline - 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.